Search the Newsreel

Lobbying Update: $10,000 of NIOCORP DEVELOPMENTS LTD. lobbying was just disclosed

NIOCORP DEVELOPMENTS LTD. (NB) disclosed $10,000 in lobbying expenditures for Q2 2026, focusing on funding and contracts related to NioCorp and US readiness. The article also details recent hedge fund activity in NB stock, with several large institutions increasing their positions, and analyst price …

BioCryst Pharmaceuticals (NASDAQ:BCRX) Share Price Passes Above Two Hundred Day Moving Average - Here's What Happened

BioCryst Pharmaceuticals (NASDAQ:BCRX) shares passed above their 200-day moving average on Thursday, trading as high as $9.48. The stock has a consensus "Moderate Buy" rating from analysts with an average target price of $20.80, despite the company reporting a wider-than-expected quarterly loss. Institutional investors …

Biocryst Pharmaceuticals Inc. (BCRX) Fundamental & Financial Data

This article provides fundamental and financial data for Biocryst Pharmaceuticals Inc. (BCRX), including its current stock price, market capitalization, dividend yield, and analyst ratings. It also highlights recent news like the appointment of a new Chief Scientific Officer and mentions that Wall Street analysts …

BCRX: Biocryst Pharmaceuticals Inc. Latest Stock Price, Analysis, News and Trading Ideas

This article provides the latest stock price, analysis, news, and trading ideas for BioCryst Pharmaceuticals Inc. (BCRX). It includes current market data such as stock price, market cap, volume, 52-week high/low, PE ratio, and recent news headlines related to the company and the biotech …

BCRX Q2'26 Earnings: revenue estimate is 183.28M USD

BioCryst Pharmaceuticals, Inc. (BCRX) is scheduled to announce its Q2'26 earnings on July 30. Analysts estimate revenue to be $183.28 million and earnings per share (EPS) at $0.15 for the quarter. The article provides a table of past reported and estimated revenue and EPS …

(BCRX) Movement Within Algorithmic Entry Frameworks

The article details an algorithmic analysis of Biocryst Pharmaceuticals Inc. (NASDAQ: BCRX), identifying divergent sentiment across various time horizons and an exceptional 48.0:1 risk-reward setup. It outlines three institutional trading strategies (Position, Momentum Breakout, and Risk Hedging) with specific entry, target, and stop-loss levels, …

How Investors May Respond To BioCryst (BCRX) Hiring Its First CSO To Drive Rare-Disease Deals

BioCryst Pharmaceuticals recently appointed David W. Jenkins as its first Chief Scientific Officer to lead efforts in external innovation and partnerships for rare disease therapies. This move signals BioCryst's commitment to expanding its pipeline beyond its primary drug, ORLADEYO, though near-term focus remains on …

Oil-linked stocks split: HPCL, Indian Oil, Asian Paints, IndiGo decline; ONGC, OIL gain as crude jumps

Bioceres Crop Solutions (BIOX) Q1 2025 earnings summary

Bioceres Crop Solutions reported a 20% year-over-year revenue decline to $93.3 million for Q1 2025, primarily due to drought in Argentina, yet saw growth in North America and Brazil. The net loss widened to $5.3 million, and Adjusted EBITDA fell by 48%. The company …

Bioceres Crop Solutions (BIOX) Registration Filing Summary

This article provides a summary of Bioceres Crop Solutions' (BIOX) Registration Filing on December 16, 2025. It details the company's business model, product portfolio, risk factors, and market opportunities in the agricultural solutions sector. The summary also lists recent financial events and their impact …

BioCryst to Report Second Quarter 2026 Financial Results on August 5

BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) announced it will report its second quarter 2026 financial results on Wednesday, August 5, 2026. Management will host a conference call and webcast at 8:30 a.m. ET on that day to discuss the results and provide a corporate update. …

BioCryst schedules a look at second-quarter results for Aug. 5

BioCryst Pharmaceuticals (Nasdaq: BCRX) announced it will report its second-quarter 2026 financial results on Wednesday, August 5, 2026. Management will host a conference call and webcast at 8:30 a.m. ET to discuss the results and provide a corporate update. The company's prior earnings-date announcements …

Can BioCryst Pharmaceuticals (BCRX) Be Worth More As A New CSO Sharpens Its Pipeline Story?

BioCryst Pharmaceuticals (BCRX) has appointed David W. Jenkins as its new Chief Scientific Officer, a move generating interest among investors. The company's stock currently trades at US$9.29, with a mixed performance of 23.87% year-to-date but a 46.14% decline over five years. A common narrative …

KIOCL Share Price Forecast: 3 Year Outlook to 2030

Citi retoma cobertura da Iochpe-Maxion (MYPK3) com previsão de melhora no 2T26, mas mantém recomendação neutra

BioCardia (BCDA) CEO Peter Altman purchases 500 shares in July 17 trade

BioCardia, Inc.'s President & CEO, Peter Altman, purchased 500 shares of common stock on July 17, 2026, at $0.83 per share in an open-market transaction. This purchase increased his direct holdings to 368,885 shares of BioCardia common stock. The transaction was not made under …

BioCryst Pharmaceuticals (BCRX) Proxy filing Summary

BioCryst Pharmaceuticals (BCRX) has announced details of its upcoming Annual Meeting scheduled for June 11, 2026. Shareholders will vote on the election of three directors, ratification of Ernst & Young LLP as auditors, an advisory vote on executive compensation, and approval of an amended …

NioCorp and Atossa Therapeutics Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

RedChip Companies will broadcast interviews with NioCorp Developments Ltd. (Nasdaq:NB) and Atossa Therapeutics, Inc. (Nasdaq:ATOS) on their "RedChip Small Stocks, Big Money™" show on Bloomberg TV this Saturday, August 30, at 7 p.m. ET. NioCorp's CEO, Mark Smith, will discuss the Elk Creek Project, …

BioCryst Pharmaceuticals (BCRX) Q4 2025 earnings summary

BioCryst Pharmaceuticals achieved record revenue and its first full-year profitability in 2025, driven by the strong performance of ORLADEYO and strategic expansions. The company reported $601.8 million in ORLADEYO revenue and $874.8 million in total revenues, with GAAP operating profit of $341 million. BioCryst …

Why Did PENG, ANET, BCRX Shares Surge To 52-Week Highs?

Penguin Solutions (PENG), Arista Networks (ANET), and Biocryst Pharmaceuticals (BCRX) all reached 52-week highs due to positive market sentiment and various catalysts. PENG benefited from increased analyst price targets driven by AI demand, ANET saw optimism for its cloud networking solutions and AI infrastructure, …

Citizens reiterates BioCryst stock rating on Orladeyo revenue outlook

Citizens maintained its Market Outperform rating on BioCryst Pharmaceuticals (NASDAQ: BCRX) with a $28 price target, citing Orladeyo revenue projections. The firm forecasts $160 million in Orladeyo revenues for Q2 2026, aligning with consensus, and $648 million for the full year 2026, slightly above …

How (AUDC) Movements Inform Risk Allocation Models

This article analyzes Audiocodes Ltd. (NASDAQ: AUDC) using AI models to inform risk allocation, indicating choppy conditions due to conflicting sentiment across different time horizons. It provides specific institutional trading strategies (Long Position, Momentum Breakout, and Risk Hedging) with entry points, targets, and stop …

ETFs Investing in AudioCodes Ltd. Stocks

This article lists various Exchange Traded Funds (ETFs) that hold stocks of AudioCodes Ltd. (AU1). It provides a detailed table including each fund's market value, weight of AudioCodes stock, issuer, management style, focus, expense ratio, AUM, price change, relative volume, and 3-year NAV total …

BioCryst Appoints David W. Jenkins as Chief Scientific Officer

BioCryst Pharmaceuticals, Inc. announced the appointment of David W. Jenkins, MA, PhD, as its new Chief Scientific Officer, effective immediately. In this role, Dr. Jenkins will focus on building and leading a research team to leverage external innovation and partnerships to accelerate the delivery …

BioCardia CEO Peter Altman buys $3,754 in company stock

BioCardia CEO Peter Altman recently purchased 4,300 shares of company common stock for a total of $3,754, with individual share prices ranging from $0.86 to $0.88. This insider buying occurred despite a recent decline in the stock's value, which has fallen 16.91% in the …

What's Going On With RioCan Real Estate Investment Trust Stock Thursday?

H.C. Wainwright Maintains NioCorp Developments(NB.US) With Buy Rating, Maintains Target Price $10

H.C. Wainwright has reiterated its Buy rating for NioCorp Developments (NB.US), maintaining a target price of $10. This indicates the firm's continued confidence in the company's prospects.

NioCorp stock holds Buy rating at H.C. Wainwright on financing outlook

H.C. Wainwright has reiterated a Buy rating and a $10.00 price target for NioCorp Developments Ltd., driven by increased confidence in the company receiving debt financing. This optimism stems from a recent $2.9 billion debt financing commitment received by Perpetua from EXIM, suggesting EXIM's …

AudioCodes Ltd. (AUDC) Q1 2026 Earnings: EPS Misses Estimates as Stock Declines 1.8% - Earnings Call Highlights

Bioceres Crop Solutions (BIOX) Edges Higher Amid Low-Price Dynamics - Strong Buy Stocks

BIOX Q2 2026 Earnings: EPS Misses Estimates Sharply, Shares Tumble 8.4% - Earnings Revision Report

Previsão MYPK3 — Preço Alvo para 2027

Ipca Laboratories Limited agreed to acquire remaining 50.35% stake in Krebs Biochemicals & Industries Limited for INR 612 million.

AUDC Forecast — Price Target — Prediction for 2027

KIOCL returns to profitability in FY26 with net profit of ₹1,657 lakh

Bioceres Crop Solutions updates earnings provision and reports court ruling